| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/BMT.2017.83 |
| P698 | PubMed publication ID | 28504666 |
| P50 | author | Yogesh Jethava | Q60979410 |
| P2093 | author name string | S Sica | |
| M Mohty | |||
| A Nagler | |||
| A Bacigalupo | |||
| B Savani | |||
| M Jagasia | |||
| F Socola | |||
| P2860 | cites work | Defining the intensity of conditioning regimens: working definitions | Q24630836 |
| Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation | Q28277744 | ||
| Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome | Q33560410 | ||
| Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma | Q33608520 | ||
| Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osse | Q68126425 | ||
| High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia | Q68132536 | ||
| Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia | Q70534802 | ||
| A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for B | Q71127546 | ||
| Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow ino | Q71654487 | ||
| Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: A Phase I/II trial | Q71868238 | ||
| A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group | Q72384744 | ||
| Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia | Q73954915 | ||
| Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases | Q74106097 | ||
| Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity | Q78605168 | ||
| Recovery of spermatogenesis after total-body irradiation | Q79407806 | ||
| Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT | Q84386943 | ||
| Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free sur | Q84730771 | ||
| Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced | Q85203904 | ||
| Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma | Q86636858 | ||
| Busulfan-based conditioning regimens: not all partners are equal | Q86643501 | ||
| Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation | Q87827813 | ||
| Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation | Q88088913 | ||
| Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia | Q33990856 | ||
| Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation | Q34033553 | ||
| Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning | Q34325244 | ||
| Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. | Q34451427 | ||
| Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation | Q34565838 | ||
| Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review | Q34770016 | ||
| Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation | Q35032266 | ||
| Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. | Q35129248 | ||
| The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia | Q35738392 | ||
| 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. | Q35849468 | ||
| The role of autologous transplantation for acute myeloid leukemia in first and second remission | Q36750647 | ||
| A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation | Q36905573 | ||
| Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring | Q37239128 | ||
| Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation | Q37370651 | ||
| Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia | Q37718826 | ||
| Algorithm for donor selection in 2011. | Q37938486 | ||
| How I treat the older patient with acute myeloid leukemia | Q38291150 | ||
| Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. | Q40475236 | ||
| Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. | Q40696043 | ||
| Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. | Q41189333 | ||
| Allogeneic stem cell transplantation for acute myeloid leukemia | Q42765065 | ||
| Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide--a phase I trial. | Q43483394 | ||
| Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor | Q43692529 | ||
| Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies | Q43819615 | ||
| Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide | Q44097089 | ||
| Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission | Q44242611 | ||
| Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study | Q45278122 | ||
| Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. | Q45745053 | ||
| Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation | Q46234145 | ||
| Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia | Q46510867 | ||
| Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome | Q46658486 | ||
| Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation | Q46666203 | ||
| Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors | Q46847870 | ||
| Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. | Q46857947 | ||
| Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes | Q46860359 | ||
| Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation | Q46870128 | ||
| Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). | Q46896197 | ||
| Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors | Q49134289 | ||
| Second malignancies after allogeneic stem cell transplantation with reduced-intensity conditioning: is the incidence reduced? | Q53019876 | ||
| Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. | Q53354602 | ||
| Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. | Q53632034 | ||
| Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. | Q53787349 | ||
| Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy | Q56777948 | ||
| Decreased Nonrelapse Mortality after Unrelated Cord Blood Transplantation for Acute Myeloid Leukemia Using Reduced-Intensity Conditioning: A Prospective Phase II Multicenter Trial | Q58158373 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1504-1511 | |
| P577 | publication date | 2017-05-15 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia | |
| P478 | volume | 52 |
| Q55515367 | Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. |
| Q57493682 | Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies |
| Q96817615 | Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity |
| Q64089200 | Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Bloo |
| Q88890106 | How I treat older patients with acute myeloid leukemia |
| Q101059389 | Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working P |
| Q90590301 | Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan |
| Q99711515 | Thymic Engraftment by in vitro-Derived Progenitor T Cells in Young and Aged Mice |
| Q91341158 | Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT |
Search more.